Study 101 evaluated the safety, tolerability, pharmacokinetics, and pharmacodynamics of PEGPH20 as a single agent, while Study 102 assessed multiple-dosing of PEGPH20 in combination with dexamethasone.
The results demonstrated that PEGPH20 treatment rapidly restored tumor perfusion and decreased metabolic activity in tumors.
Moreover, Dynamic Contrast Enhanced Magnetic Resonance Imaging (DCE-MRI) showed that the imaging agent was able to access a pancreatic tumor more easily post-administration of PEGPH20.